Transcriptional silencing by CpG island hypermethylation of gene regulatory regions is one mechanism for inactivation of tumour suppressor genes. Chromosome 9q deletion is frequently found in transitional cell carcinoma (TCC) of the bladder and upper urinary tract and one of the putative tumour suppressor loci has been mapped to 9q32-33. A gene designated as DBCCR1 was identi®ed in the candidate region and its mRNA expression is thought to be suppressed by hypermethylation. To understand the role of hypermethylation in TCC, we evaluated the methylation status of 20 CpG sites of the DBCCR1 5'-CpG island region in a total of 69 tumours from 45 patients, 21 normal urothelial specimens, and six bladder cancer cell lines. Aberrant hypermethylation levels were found in 36 (52%) of 69 tumours without any association with tumour grade or stage. Methylation was weakly detected in the normal urothelium in association with ageing. Although recurrent tumours tended to have higher methylation levels than the initial tumours, the methylation pattern was mostly maintained between multifocal TCCs in individual patients. The results suggest that hypermethylation of the DBCCR1 region is one of the earliest alterations in the development of TCCs and there may be an age-related hypermethylation-based ®eld defect in normal urothelium. Methylator or methylation-resistant phenotype seems to be maintained during multifocal development or recurrence of most TCCs. Oncogene (2001) 20, 531 ± 537.
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Mammalian DNA methylation is a covalent modi®ca-tion of cytosine residues, predominantly at CpG dinucleotides, and the methylation pattern in somatic cells is generally well maintained with normal cell division (Ceder and Razin, 1990) . In contrast, isolated CpG dinucleotides in bulk chromatin are often methylated, whereas cytosine residues in CpG islands are unmethylated and such islands are mostly located in the promoters or coding regions of genes (Cross and Bird, 1995) . Accumulating evidence shows that aberrant hypermethylation at CpG dinucleotides in normally unmethylated CpG islands of gene promoter regions may repress gene expression. In fact, transcriptional silencing of tumour suppressor genes, such as the RB1 gene (Sakai et al., 1991) , the VHL gene (Herman et al., 1994) and the p16 gene Gonzalez-Zulueta et al., 1995; Herman et al., 1995) , by aberrant hypermethylation of regulatory sequences has been reported. Hypermethylation of CpG dinucleotides in CpG islands may constitute an alternative mechanism to intragenic mutations or gene deletions for the inactivation of tumour suppressor genes (Cross et al., 1995; Jones and Laird, 1999) .
Transitional cell carcinomas (TCCs) of the bladder, ureter and renal pelvis are among the most common human cancers and have a few distinct characteristics (Messing and Catalona, 1998) . The majority of TCCs are low-grade non-invasive tumours which occur often in heterotropic urothelium but progress infrequently to the invasive phenotype. In contrast, muscle-invasive TCCs often metastasize to other organs and have a poor prognosis, and is therefore considered a systemic disease. In addition, TCCs are characterized by common synchronous and/or metachronous multifocal development throughout the urothelium. Recent molecular genetic studies have shown that loss of heterozygosity (LOH) on chromosome 9q is one of the most frequent genetic alterations and is found consistently in all stages and grades of TCC, indicating the presence of an important tumour suppressor gene(s) on 9q (Knowles et al., 1994; Habuchi et al., 1995) . Detailed LOH studies on 9q have indicated that there are multiple tumour suppressor loci for TCC (Habuchi et al., 1995 (Habuchi et al., , 1997 . One of the putative tumour suppressor loci on 9q was mapped at 9q32-33 (DBC1) and a gene designated as DBCCR1 (deleted in bladder cancer chromosomal region candidate 1) was identi®ed (Habuchi et al., 1997 . Although it is unclear if DBCCR1 is a real tumour suppressor gene, exon 1 is very rich in CpG sites and conforms to the criteria for Oncogene (2001) 20, 531 ± 537 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc a CpG island . Furthermore, its mRNA expression appears to be suppressed by hypermethylation of the 5'-region, which is frequently found in TCCs in vivo and in vitro . However, the biological signi®cance of the hypermethylation of the DBCCR1 5'-region is unclear. It also remains unknown whether this is an early or late event in the development of TCCs and whether hypermethylation is a tumour-speci®c alteration.
In the present study, we have tried to delineate the timing and biological signi®cance of hypermethylation of the DBCCR1 5'-region at the 9q32-33 candidate tumour suppressor locus. A total of 69 urothelial TCC specimens from 45 patients, 21 normal urothelial specimens, and six bladder cancer cell lines were included in this study.
Exon 1 of DBCCR1 is non-coding and has been shown to conform to the criteria of the CpG island Gardiner-Garden and Frommer, 1987) . The selected 218 bp region containing 21 CpG sites of the exon 1 was ampli®ed from bisul®te-modi®ed DNA by PCR and directly sequenced ( Figure  1a ). The methylation status of the region and the presence of its mRNA expression in the six bladder cancer cell lines are summarized in Figure 1b ). RT ± PCR analysis of DBCCR1 mRNA expression revealed that cell lines RT112, 253J and UMUC3 showed expression of DBCCR1 mRNA, whereas there was no expression in cell lines T24, 5637 and HT1197. The result was in accord with the previous study . Sequencing of bisul®te-treated genomic DNA showed partial to complete methylation at all the 20 CpG sites in the T24 and 5637 cell lines, and partial to complete methylation at more than the 16 CpG sites in the 253J and UMUC3 cell lines (Figure 1b) . Therefore, there seemed to be no clear association between the extent of methylation and the mRNA expression level. Furthermore, there was no speci®c site for methylation that was associated with loss of mRNA expression among the 20 CpG sites.
Because it is unknown whether hypermethylation in this region is urothelial cancer speci®c or whether it is present even in normal urothelium, we examined the methylation status of the DBCCR1 5'-region in the normal urothelium from 21 subjects ranging in age from six to 80 years. Methylation of several of the 20 CpG sites seemed to be correlated with ageing. By scoring the methylation level at each CpG site based on the ratio of electrophoretogram intensity of cytosine and thymine as described, the methylation score was plotted against the age of the subjects (Figure 2) . A regression analysis of all normal samples gave a linear ®t with a correlation coecient of 0.389 (R squared), Vertical arrows indicate methylated CpG sites. *=thymines modi®ed by bisul®te treatment from cytosines at non-CpG sites. Genomic DNA extracted from the tumour and normal samples was treated with sodium bisul®te as described previously (Frommer et al., 1992) . The selected 218 bp region containing 20 CpG sites of the exon 1 of the DBCCR1 was ampli®ed from bisul®te-modi®ed DNA by PCR. PCR primer sequences speci®c for bisul®te-converted DNA were 5'-GGATTTTA(T/C) GGTTGTAAATTGATTG (forward, modi®ed from nt 11 ± 36 by GenBank Accession No. AF027734) and 5'-CCTAACAACC-TAACTCATACTCAAC (reverse, modi®ed from nt 206 ± 230). DNA sequencing was performed by ABI PRISM TM 377 (PE Applied Biosystems). Since unmethylated cytosines appeared as thymines, whereas methylated cytosines remained as cytosines after bisul®te modi®cation, methylation status was determined by comparing the intensity of sequencing electropherogram of cytosine with that of thymine at each CpG site. When the intensity of cytosine was less than 20% that of thymine, the CpG site was de®ned as having`no methylation' and was given a methylation score of`0'. When the intensity of cytosine was from 20 ± 50% that of thymine, the site was de®ned as having`minor methylation' and given a score of`1'. When the intensity of cytosine was from 50 ± 200% that of thymine, the site was de®ned as having`partial methylation' and given a score of`2'. When the intensity of cytosine was more than 200% that of thymine, the site was de®ned as having`complete methylation' and given a score of`4'. Since the intensity of the sequencing electropherogram varies according to surrounding nucleotide sequences and is not absolutely quantitative, our evaluation for methylation status at each CpG site was considered as semi-quantitative. (b) Methylation pro®les of 20 CpG sites in the DBCCR1 5'-region in six bladder cancer cell lines. DBCCR1 mRNA expression was determined by RT ± PCR analysis as described elsewhere , with a minor modi®cation. MS=total methylation score. White circles=No methylation, scored as`0'. Dotted circles=minor methylation, scored as`1'. Striated circles=partial methylation, scored as`2'. Black circles=complete methylation, scored as`4'. *denotes a mutation or polymorphism at this CpG site (G to T), resulting in the removal of the CpG sequence which is considered to be statistically signi®cant (P=0.0025, Figure 2 ). There was a variation in the degree of hypermethylation between each CpG site, since some CpG sites showed frequent partial methylation (data not shown), whereas other sites were almost completely free from methylation.
Since the chronological tracing of genetic and epigenetic alterations is possible by studying synchronous or metachronous multifocal TCCs (Takahashi et al., 1998) , we then tested the methylation status of the DBCCR1 5'-region in 44 multifocal tumours from 21 patients. All these tumours were tested for microsatellite alterations in the previous study (Takahashi et al., 1998) . Methylation pro®les of multifocal tumours with concordant microsatellite alterations are shown in Figure 3a and those of tumours with discordant microsatellite alterations in Figure 3b . Partial or complete methylation at eight or more CpG sites was found in 13 (48%) of 27 tumours in the concordant group and four (22%) of 18 tumours in the disconcordant group (P=0.073, Fisher's exact test). Next, the methylation pattern was compared between tumours in each patient with multifocal tumours. Five (24%) of the 21 patients showed a discordant methylation pattern at four or more CpG sites tested. A discordant methylation pattern at four or more sites was found in one (17%) of six patients with synchronous multifocal tumours and four (27%) of 15 patients with metachronous multifocal tumours (P40.99, Fisher's exact test). These results indicated that methylation patterns were maintained in the majority of CpG sites in most multifocal tumours. In metachronous tumours, recurrent tumours seemed to have a tendency to harbour higher methylation status than the initial tumours tested. Of the 18 evaluable pairs of metachronous tumours, 13 (72%) recurrent tumours had higher methylation scores than the initial tumours, whereas only four recurrent tumours had lower methylation scores. This deviation toward the higher methylation scores was statistically signi®cant (P=0.0395, Wilcoxon signed rank test).
Recent studies have suggested that hypermethylation of the CpG island of some genes is associated with tumour progression (Issa et al., 1997; Toyota et al., 1999; Maesawa et al., 1996) while that of other genes is an early event in the tumorigenesis (Sakai et al., 1991; Herman et al., 1994; Issa et al., 1994; Ahuja et al., 1998) . To determine whether hypermethylation of the DBCCR1 5'-region is associated with tumour progression, we examined 24 urothelial cancers consisting of 10 low grade (grade 1 or 2) ± low stage (Ta or T1) tumours and 14 high grade (grade 3) ± high stage (pT2 or more) tumours (data not shown). The dierence in the methylation score between the two groups was not statistically signi®cant (P=0.953, the Mann ± Whitney U-test). Next, by combining the data of the multifocal tumour cases, the methylation scores of all the tested tumours were plotted with box-and-whiskers according to tumour grade and tumour stage (Figure 4) . The statistical analysis showed no signi®cant dierence in the methylation score between any combination of groups divided by tumour grade or stage (P=0.673 for tumour grade, P=0.154 for tumour grade, the Kruskal-Wallis test). Since most urothelial cancer patients are over 50 years old (only three (7%) of 45 TCC patients in this study were under 50 years old), we calculated the normal level of methylation in men over 50 years old. Of the 21 normal urothelium, 12 subjects met this criteria and the mean+s.d. (standard deviation) of the methylation score was 10.9+5.2. If the cut-o value was placed at mean+26s.d., the methylation scores of 22 or more might be considered to be abnormal. With this criteria, 36 (52%) of 69 tumours in total were judged to have an abnormal hypermethylation level of the DBCCR1 5'-region. Abnormal hypermethylation was found in seven (54%) of 13 grade 1, 21 (50%) of 42 grade 2, and eight (57%) of 14 grade 3 tumours (P40.05, Chisquare test). As for tumour stage, the abnormal hypermethylation was found in 12 (39%) of 31 pTa, 13 (72%) of 18 pT1 and nine (53%) of 17 pT2-4 or metastatic tumours (P40.05, Chi-square test).
The present study shows that the DBCCR1 5'-region is a frequent (about 50% or more) target of aberrant hypermethylation in TCCs in vivo. However, there was no clear relationship between DBCCR1 mRNA expression and the hypermethylation pattern. In the previous study, de novo re-expression of DBCCR1 mRNA was found in T24 and 5637 cell lines after treatment with the demethylating agent 5-aza-2'-deoxycytidine , indicating that hypermethylation-based silencing is involved in the DBCCR1 mRNA silencing. Because the CpG island tested in this study is located in the 3'-region of the transcription start site and the CpG-rich region extends to 5' (MA Knowles, unpublished data) , it is probable that there are other CpG sites or a CpG-rich region which are critical for the regulation of mRNA expression. Since gene silencing by CpG methylation seems to be somewhat dependent Figure 2 Ageing and methylation of the DBCCR1 5'-region. The methylation score from normal urothelium calculated by the cytosine to thymine ratio of direct sequencing of bisul®te-modi®ed DNA is plotted against the age of 21 non-cancer urologic patients or healthy kidney donors. Normal transitional cell epithelium was peeled away from submucosal connective tissue and subjected to DNA extraction. A regression analysis of the 21 samples gave a linear ®t and was statistically signi®cant (P=0.0025) on the CpG methylation density (Hsieh, 1994) and methylation status in the promoter region which is not transcribed (Jones, 1999) , more extensive methylation mapping would reveal a clearer relationship between the methylation level of the DBCCR1 5'-region and its mRNA expression.
Although it has not yet been clari®ed whether DBCCR1 is a real tumour suppressor, several lines of evidence show that the region containing DBCCR1 is a strong candidate tumour suppressor locus (Habuchi, 1997; Nishiyama et al., 1999; van Tilborg et al., 1999) . The frequent hypermethylation in TCCs and the presence of hypermethylation in the normal urothelium suggests that the region is an easy and frequent target of random CpG hypermethylation. Such random CpG hypermethylation may give rise to reduced expression of genes in this region and increased heterochromatinization, leading to clonal selection of transitional cells with abnormal hypermethylation, as observed in the present study (Jones, 1996 (Jones, , 1999 . It would be interesting to know if the frequent hypermethylation in the region has any biological relationship with frequent occurrence of LOH on 9q in TCCs. LOH on 9q coupled with hypermethylation-based gene silencing of the remaining allele may be one of the major mechanisms for the inactivation of a tumour suppressor gene at the 9q32-33 locus. While hypermethylation of the CpG island of some genes may be associated with tumour progression (Issa et al., 1997; Toyota et al., 1999; Maesawa et al., 1996) , our data suggests that the hypermethylation of the DBCCR1 5'-region is an early event in the development of TCCs. It remains to be seen whether the early occurrence of hypermethylation at this locus is related to the fact that the LOH at 9q32-33 is one of the earliest events in the development of TCC.
The presence of the age-related methylation in the normal urotherlium supports the conclusion that a Hypermethylation at 9q32-33 region in urothelial cancer T Habuchi et al hypermethylation in this region is an early event in the development of TCC. Such age-related progressive methylation has been reported in the CpG islands of a few candidate tumour suppressor genes ± Estrogen receptor (Issa et al., 1994) , N33 Ahuja et al., 1998) , an imprinted IGF2 and a proto-oncogene c-fos (Choi et al., 1996) . In colorectal mucosal cells, age-related methylation seems to be both gene-speci®c and tissue-speci®c . Although the hypermethylation level of normal urothelium was much lower than that of TCCs, the weak age-related methylation could be the basis of ®eld-cancerization of the urothelium and may be related to the fact that most TCCs are found in the aged population (Messing and Catalona, 1998) . Furthermore, evidence for the methylation-based ®eld cancerization of the normal urothelium in bladder cancer patients has been observed by Muto et al. (2000) . Because of a considerable dierence in the extent of methylation of normal urothelium even in age-matched subjects (Figure 2 ), it would be interesting to know whether it is caused by a dierence in exposure to carcinogens or a dierence in genetic or endogenous factors to maintain the integrity of the CpG methylation pattern. Furthermore, it is critical to ascertain whether the hypermethylated normal urothelium is more susceptible to development of TCC. If this is the case, drugs to inhibit de novo DNA methylation could be useful for preventing the development of TCC in a subset of individuals with methylator phenotype.
Our results indicate that the methylation pattern of most multifocal tumours is maintained in each patient, irrespective of other microsatellite alterations or LOH. TCCs with methylator phenotype or TCCs with methylation-resistant phenotype tended to maintain their phenotype during the multifocal development or heterotopic recurrence. Furthermore, a striking dierence in methylation levels according to each tumour and each cell line suggests that there is a phenotype of extensive CpG methylation. The results warrant further study to clarify the cause of this CpG methylator phenotype, such as altered regulation of DNA methyltransferase genes (Issa, 1999) .
In conclusion, hypermethylation of the DBCCR1 5'-region at 9q32-33 is frequent and one of the earliest alterations in the development of TCCs. There is age- (Mosto® et al., 1973) . S=tumour stage (T-category) by TNM classi®cation (UICC, 1992) . Annotations for circles are the same as those shown in Figure 1 . In the microsatellite alteration column, -S and -L represent microsatellite shift (instability) and loss of heterozygosity, respectively. The results for microsatellite analysis were published previously (Takahashi et al., 1998) . In comparing the methylation status at each CpG site between multifocal tumours in a single patient, the methylation status was de®ned as`discordant' when there was a 2-degree dierence (i.e.; from`minor methylation' to`complete methylation', from`no methylation' to`partial methylation', or vice versa) between two tumours related hypermethylation in the normal urothelium, which could be the basis of a ®eld defect in the aged urothelium. Methylator or methylation-resistant phenotype seems to be maintained during multifocal development or recurrence of most TCCs. 
